EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood

European Journal of Neurology

Volumn 21, Issue 4, 2014, Pages 552-562

  Van de Warrenburg, B P C ^a   van Gaalen, J ^a   Boesch, S ^b   Burgunder, J M ^c   Durr A ^d,e   Giunti, P ^f   Klockgether, T ^g   Mariotti, C ^h   Pandolfo, M ⁱ   Riess, O ^j  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF BERN   (Switzerland)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e CNRS   (France)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h DEPARTMENT OF NEUROSURGERY   (Italy)

ⁱ ERASME HOSPITAL   (Belgium)

^j UNIVERSITY OF TÜBINGEN   (Germany)

more..

Author keywords

Ataxia; Genetic testing; MRI; Multiple system atrophy; Symptomatic treatment

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; CHENODEOXYCHOLIC ACID; IDEBENONE; MIGLUSTAT; RETINOL; RILUZOLE; THIAMINE;

ACUTE ATAXIA; ADULT; ADULTHOOD; ARTICLE; ATAXIA; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CEREBELLAR ATAXIA; CHRONIC ATAXIA; CLINICAL CLASSIFICATION; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL (TOPIC); COST; DENTATORUBROPALLIDOLUYSIAN ATROPHY; FAMILY HISTORY; GENETIC HETEROGENEITY; GENETIC SCREENING; HEALTH CARE; HUMAN; MEDICAL SPECIALIST; NEUROLOGIST; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINOCEREBELLAR DEGENERATION; SUBACUTE ATAXIA; SYSTEMATIC REVIEW (TOPIC);

ATAXIA; GENETIC TESTING; MRI; MULTIPLE SYSTEM ATROPHY; SYMPTOMATIC TREATMENT;

ATAXIA; CHRONIC DISEASE; CONSENSUS; DATABASES, FACTUAL; GUIDELINES AS TOPIC; HUMANS;

EID: 84897920084     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12341     Document Type: Article

References (89)

1. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. Eur J Neurol 2004; 11: 577-581.
2. Gasser T, Finsterer J, Baets J, et al. EFNS guidelines on the molecular diagnosis of ataxias and spastic paraplegias. Eur J Neurol 2010; 17: 179-188.
3. Finsterer J, Harbo HF, Baets J, et al. EFNS guidelines on the molecular diagnosis of mitochondrial disorders. Eur J Neurol 2009; 16: 1255-1264.
4. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18: 19-e3.
5. Sequeiros J, Martindale J, Seneca S, et al. EMQN Best Practice Guidelines for molecular genetic testing of SCAs. Eur J Hum Genet 2010; 18: 1173-1176.
6. van GJ, van de Warrenburg BP. A practical approach to late-onset cerebellar ataxia: putting the disorder with lack of order into order. Pract Neurol 2012; 12: 14-24.
7. van de Warrenburg BP, Sinke RJ, Verschuuren-Bemelmans CC, et al. Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology 2002; 58: 702-708.
8. Cagnoli C, Stevanin G, Michielotto C, et al. Large pathogenic expansions in the SCA2 and SCA7 genes can be detected by fluorescent repeat-primed polymerase chain reaction assay. J Mol Diagn 2006; 8: 128-132.
9. Mao R, Aylsworth AS, Potter N, et al. Childhood-onset ataxia: testing for large CAG-repeats in SCA2 and SCA7. Am J Med Genet 2002; 110: 338-345.
10. Stevanin G, Durr A, Benammar N, Brice A. Spinocerebellar ataxia with mental retardation (SCA13). Cerebellum 2005; 4: 43-46.
11. Vlak MH, Sinke RJ, Rabelink GM, Kremer BP, van de Warrenburg BP. Novel PRKCG/SCA14 mutation in a Dutch spinocerebellar ataxia family: expanding the phenotype. Mov Disord 2006; 21: 1025-1028.
12. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 2010; 9: 885-894.
13. Verbeek DS, van de Warrenburg BP. Genetics of the dominant ataxias. Semin Neurol 2011; 31: 461-469.
14. Goizet C, Lesca G, Durr A. Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias. Neurology 2002; 59: 1330-1336.
15. Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. N Engl J Med 2012; 366: 636-646.
16. Anheim M, Fleury M, Monga B, et al. Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. Neurogenetics 2010; 11: 1-12.
17. Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord 2007; 22: 2018-2030, quiz.
18. Apartis E, Blancher A, Meissner WG, et al. FXTAS: new insights and the need for revised diagnostic criteria. Neurology 2012; 79: 1898-1907.
19. Fernandes M, Munhoz RP, Carrilho PE, et al. Neurological disorders associated with glutamic acid decarboxylase antibodies: a Brazilian series. Arq Neuropsiquiatr 2012; 70: 657-661.
20. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131: 2553-2563.
21. Virgilio R, Corti S, Agazzi P, et al. Effect of steroid treatment in cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry 2009; 80: 95-96.
22. Burk K, Bosch S, Muller CA, et al. Sporadic cerebellar ataxia associated with gluten sensitivity. Brain 2001; 124: 1013-1019.
23. Abele M, Schols L, Schwartz S, Klockgether T. Prevalence of antigliadin antibodies in ataxia patients. Neurology 2003; 60: 1674-1675.
24. Bushara KO, Goebel SU, Shill H, Goldfarb LG, Hallett M. Gluten sensitivity in sporadic and hereditary cerebellar ataxia. Ann Neurol 2001; 49: 540-543.
25. Hadjivassiliou M, Grunewald R, Sharrack B, et al. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. Brain 2003; 126: 685-691.
26. Ihara M, Makino F, Sawada H, et al. Gluten sensitivity in Japanese patients with adult-onset cerebellar ataxia. Intern Med 2006; 45: 135-140.
27. Liu CS, Soong BW, Lee YC, et al. Gluten sensitivity: associated sporadic cerebellar ataxia in Taiwan. Acta Neurol Taiwan 2010; 19: 263-269.
28. Lock RJ, Pengiran Tengah DS, Unsworth DJ, Ward JJ, Wills AJ. Ataxia, peripheral neuropathy, and anti-gliadin antibody. Guilt by association? J Neurol Neurosurg Psychiatry 2005; 76: 1601-1603.
29. Almaguer-Mederos LE, Almira YR, Gongora EM, et al. Antigliadin antibodies in Cuban patients with spinocerebellar ataxia type 2. J Neurol Neurosurg Psychiatry 2008; 79: 315-317.
30. Wong D, Dwinnel M, Schulzer M, et al. Ataxia and the role of antigliadin antibodies. Can J Neurol Sci 2007; 34: 193-196.
31. Hadjivassiliou M, Aeschlimann P, Sanders DS, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology 2013; 80: 1740-1745.
32. Anandacoomaraswamy D, Ullal J, Vinik AI. A 70-year-old male with peripheral neuropathy, ataxia and antigliadin antibodies shows improvement in neuropathy, but not ataxia, after intravenous immunoglobulin and gluten-free diet. J Multidiscip Healthc 2008; 1: 93-96.
33. Bhatia KP, Brown P, Gregory R, et al. Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Brain 1995; 118(Pt 5): 1087-1093.
34. Burk K, Melms A, Schulz JB, Dichgans J. Effectiveness of intravenous immunoglobin therapy in cerebellar ataxia associated with gluten sensitivity. Ann Neurol 2001; 50: 827-828.
35. Burk K, Farecki ML, Lamprecht G, et al. Neurological symptoms in patients with biopsy proven celiac disease. Mov Disord 2009; 24: 2358-2362.
36. Habek M, Hojsak I, Barun B, Brinar VV. Downbeat nystagmus, ataxia and spastic tetraparesis due to coeliac disease. Neurol Sci 2011; 32: 911-914.
37. Hadjivassiliou M, vies-Jones GA, Sanders DS, Grunewald RA. Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry 2003; 74: 1221-1224.
38. Hermaszewski RA, Rigby S, Dalgleish AG. Coeliac disease presenting with cerebellar degeneration. Postgrad Med J 1991; 67: 1023-1024.
39. Muller AF, Donnelly MT, Smith CM, et al. Neurological complications of celiac disease: a rare but continuing problem. Am J Gastroenterol 1996; 91: 1430-1435.
40. Nanri K, Okita M, Takeguchi M, et al. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med 2009; 48: 783-790.
41. Pellecchia MT, Scala R, Perretti A, et al. Cerebellar ataxia associated with subclinical celiac disease responding to gluten-free diet. Neurology 1999; 53: 1606-1608.
42. Siqueira Neto JI, Costa AC, Magalhaes FG, Silva GS. Neurological manifestations of celiac disease. Arq Neuropsiquiatr 2004; 62: 969-972.
43. Souayah N, Chin RL, Brannagan TH, et al. Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol 2008; 15: 1300-1303.
44. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676.
45. Abele M, Burk K, Schols L, et al. The aetiology of sporadic adult-onset ataxia. Brain 2002; 125: 961-968.
46. Schols L, Szymanski S, Peters S, et al. Genetic background of apparently idiopathic sporadic cerebellar ataxia. Hum Genet 2000; 107: 132-137.
47. Apartis E, Blancher A, Meissner WG, et al. FXTAS: new insights and the need for revised diagnostic criteria. Neurology 2012; 79: 1898-1907.
48. Adams SA, Steenblock KJ, Thibodeau SN, Lindor NM. Premutations in the FMR1 gene are uncommon in men undergoing genetic testing for spinocerebellar ataxia. J Neurogenet 2008; 22: 77-92.
49. Brussino A, Gellera C, Saluto A, et al. FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia. Neurology 2005; 64: 145-147.
50. Cellini E, Forleo P, Ginestroni A, et al. Fragile X premutation with atypical symptoms at onset. Arch Neurol 2006; 63: 1135-1138.
51. Kamm C, Healy DG, Quinn NP, et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 2005; 128: 1855-1860.
52. Macpherson J, Waghorn A, Hammans S, Jacobs P. Observation of an excess of fragile-X premutations in a population of males referred with spinocerebellar ataxia. Hum Genet 2003; 112: 619-620.
53. Reis AH, Ferreira AC, Gomes KB, et al. Frequency of FMR1 premutation in individuals with ataxia and/or tremor and/or parkinsonism. Genet Mol Res 2008; 7: 74-84.
54. Tan EK, Zhao Y, Puong KY, et al. Fragile X premutation alleles in SCA, ET, and parkinsonism in an Asian cohort. Neurology 2004; 63: 362-363.
55. Van EH, Dom R, Bex D, et al. Screening for FMR-1 premutations in 122 older Flemish males presenting with ataxia. Eur J Hum Genet 2005; 13: 121-123.
56. Ubhi K, Low P, Masliah E. Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci 2011; 34: 581-590.
57. Stefanova N, Bucke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8: 1172-1178.
58. Wenning GK, Krismer F, Poewe W. New insights into atypical parkinsonism. Curr Opin Neurol 2011; 24: 331-338.
59. Gabsi S, Gouider-Khouja N, Belal S, et al. Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency. Eur J Neurol 2001; 8: 477-481.
60. Mariotti C, Gellera C, Rimoldi M, et al. Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurol Sci 2004; 25: 130-137.
61. Amiel J, Maziere JC, Beucler I, et al. Familial isolated vitamin E deficiency. Extensive study of a large family with a 5-year therapeutic follow-up. J Inherit Metab Dis 1995; 18: 333-340.
62. Schuelke M, Mayatepek E, Inter M, et al. Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency. J Pediatr 1999; 134: 240-244.
63. Bonnot O, Fraidakis MJ, Lucanto R, et al. Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic acid. CNS Spectr 2010; 15: 231-236.
64. Federico A, Dotti MT. Treatment of cerebrotendinous xanthomatosis. Neurology 1994; 44: 2218.
65. Ito S, Kuwabara S, Sakakibara R, et al. Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis. J Neurol Sci 2003; 216: 179-182.
66. Chien YH, Peng SF, Yang CC, et al. Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C. J Inherit Metab Dis 2012; 36: 129-137.
67. Di RM, Dardis A, Madeo A, Barone R, Fiumara A. Early miglustat therapy in infantile Niemann-Pick disease type C. Pediatr Neurol 2012; 47: 40-43.
68. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007; 6: 765-772.
69. Patterson MC, Hendriksz CJ, Walterfang M, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 2012; 106: 330-344.
70. Chowers I, Banin E, Merin S, Cooper M, Granot E. Long-term assessment of combined vitamin A and E treatment for the prevention of retinal degeneration in abetalipoproteinaemia and hypobetalipoproteinaemia patients. Eye (Lond) 2001; 15: 525-530.
71. Zamel R, Khan R, Pollex RL, Hegele RA. Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis 2008; 3: 19.
72. Wright TL, Heyworth ME. Maldigestion and malabsorption. Gastrointestinal Disease. Pathophysiology, Diagnosis and Management. Philadelphia, PA: WB Saunders, 1989.
73. Gibberd FB, Wierzbicki AS. Heredopathia atactica polyneuritiformis: Refsum's disease. Handbook of Ataxia Disorders. New York, NY: Marcel Dekker, 2000.
74. Baldwin EJ, Gibberd FB, Harley C, et al. The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. J Neurol Neurosurg Psychiatry 2010; 81: 954-957.
75. Horvath R, Czermin B, Gulati S, et al. Adult-onset cerebellar ataxia due to mutations in CABC1/ADCK3. J Neurol Neurosurg Psychiatry 2012; 83: 174-178.
76. Lagier-Tourenne C, Tazir M, Lopez LC, et al. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet 2008; 82: 661-672.
77. Mollet J, Delahodde A, Serre V, et al. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am J Hum Genet 2008; 82: 623-630.
78. Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F, Carrillo-Fumero R. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord 2009; 24: 1111-1124.
79. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010; 74: 839-845.
80. Zesiewicz TA, Sullivan KL. Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14). Clin Neuropharmacol 2008; 31: 363-365.
81. Zesiewicz TA, Sullivan KL, Gooch CL, Lynch DR. Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix). J Clin Neuromuscul Dis 2009; 10: 191-193.
82. Zesiewicz TA, Sullivan KL, Freeman A, Juncos JL. Treatment of imbalance with varenicline Chantix(R): report of a patient with fragile X tremor/ataxia syndrome. Acta Neurol Scand 2009; 119: 135-138.
83. Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 2012; 78: 545-550.
84. Botez MI, Young SN, Botez T, Pedraza OL. Treatment of heredo-degenerative ataxias with amantadine hydrochloride. Can J Neurol Sci 1991; 18: 307-311.
85. Botez MI, Botez-Marquard T, Elie R, et al. Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study. J Neurol Neurosurg Psychiatry 1996; 61: 259-264.
86. Filla A, De MG, Orefice G, et al. A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia. Can J Neurol Sci 1993; 20: 52-55.
87. Kearney M, Orrell RW, Fahey M, Pandolfo M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev 2012; 4: CD007791.
88. Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003; 60: 1676-1679.
89. Fonteyn EM, Keus SH, Verstappen CC, et al. The effectiveness of allied health care in patients with ataxia: a systematic review. J Neurol 2013; PMID: 23589192. [Epub ahead of print].